Access! 2023 + IGBA 2023 Conference - Last chance to register, join us in Orlando, FL on Feb 13-16!
  • Fireside chat with Mark Cuban at Access! 2023
    Fireside Chat with Mark Cuban
    Join us in Orlando, Florida on February 13-16, 2023 for a fireside chat with Mark Cuban, the founder of the Mark Cuban Cost Plus Drug Company at Access! 2023. Register now!
  • 2021 Savings for Patients by Condition
    Generic and biosimilar medicines improve access and affordability for the millions of people with illnesses like asthma, arthritis, heart disease, and depression. Learn more and download fact sheets about the savings by common patient conditions.
  • Access! 2023 - AAM Annual Meeting
    Access! 2023 and 25th IGBA Conference
    Two Conferences – One Location. Make plans to attend Access! 2023 and the 25th IGBA conference, February 13-16 in Orlando, Florida. Meet the leaders and decision-makers who are shaping the future of generics and biosimilars.
  • AAM 2022 U.S. Generic and Biosimilar Medicines Savings Report
    2022 U.S. Generic & Biosimilar Medicines Savings Report
    Savings continue to grow with $373B saved in 2021 the U.S. health care system, including patients, employers, and taxpayers. With 91% of Rx filled and only 18% of Rx drug spending, findings reinforce the critical importance of the generic and biosimilar industry to America’s patients.
  • IQVIA White Paper: Pharmacy Discount Card Utilization and Impact
    Explosive Growth in Drug Discount Cards is a Symptom of a Broken System
    A new white paper from IQVIA shines light not only on the growth of these cards, but also on how much patients are unnecessarily spending on low-cost generic drugs.
  • AAM Voices of Access
    AAM Voices of Access
    Physicians, pharmacists, patients and caregivers across the country trust generics and biosimilars. Here are their stories, in their own words—along with perspectives from health care professionals and the AAM team.
  • Markup Madness
    Who’s Profiting from Your Prescription?
    Unlike brand drugs where the manufacturer stands to profit the most, generic medicines are often exploited by middlemen that seize significant profits at the expense of patients and the companies that make the medicines.

Error message

An illegal choice has been detected. Please contact the site administrator.

Recent Updates

No content available.

Our Brands and Campaigns

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.